Push 29080 records

29,080 records0 files14 MiB total4 types
via nih-clinical-trials/1.0Jun 12, 2026ulv3:0fe1a35c4881…ark:12345/ulr1bn5nb6jsbfx.v1.0.0
idnctIdtitlestatussponsorIdbriefSummarycompletionDateconditionsenrollmentCountenrollmentTypephasestartDatestudyTypeurl
NCT00000171NCT00000171Study of Melatonin: Sleep Problems in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThis protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime…—["Alzheimer Disease","Dyssomnias"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000171
NCT00000172NCT00000172Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration RegimenCOMPLETEDjanssen-lpGalantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive …—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000172
NCT00000173NCT00000173A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)COMPLETEDnational-institute-on-aging-niaThe National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not demen…2004-01["Alzheimer Disease"]——PHASE31999-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000173
NCT00000174NCT00000174Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)COMPLETEDnovartisThis phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diag…—["Alzheimer Disease","Cognition Disorders"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000174
NCT00000176NCT00000176Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.COMPLETEDnational-institute-on-aging-niaThis is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.2007-09["Alzheimer Disease","Memory Disorders"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000176
NCT00000177NCT00000177Estrogen Hormone ProtocolCOMPLETEDnational-institute-on-aging-niaEstrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because thi…1999-01["Alzheimer Disease"]120—PHASE31995-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000177
NCT00000178NCT00000178Multicenter Trial of Prednisone in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThis is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or…—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000178
NCT00000179NCT00000179Agitation in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaAgitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness. These behaviors often make caring for …—["Alzheimer Disease"]——PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00000179
NCT00001235NCT00001235Biochemical and Genetic Studies in Familial Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsAlzheimer's disease is a condition marked by the deterioration of mental function. The disease usually begins in late middle life and results in death in 5 to 10 years. Patients with Alzheimer's disea…2004-02["Alzheimer's Disease","Nervous System Disease"]1500——1988-02OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001235
NCT00001480NCT00001480The Evaluation and Follow-up of Patients With Memory Disorder and Normal ControlsCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to evaluate people with mild memory problems, those with dementia, those at risk for developing Alzheimer's disease (AD), and healthy volunteers to identify markers of AD …2007-03-31["Alzheimer's Disease","Dementia","Healthy","Memory Disorder"]750——1995-03-21OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001480
NCT00001549NCT00001549Diagnosis and Natural History Protocol for Patients With Neurological ConditionsCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThe purpose of this study is to improve understanding of neurological conditions. Patients participating in this study will continue receiving medical care, routine laboratory tests, and diagnostics t…2006-01["Alzheimer's Disease","Dementia","Movement Disorder","Multiple System Atrophy","Parkinson's Disease"]600——1995-10OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001549
NCT00001662NCT00001662Tolerability and Primary Efficacy of CX516 in Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsGlutamate is an amino acid released by brain cells that acts to excite other cells. Glutamate attaches to special sites on cells called AMPA (alpha-amino-2,3-dihydro-5 methyl 3-oxo-4-isoxazolepropanoi…2005-11["Alzheimer's Disease","Dementia"]40—PHASE21996-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00001662
NCT00001917NCT00001917M2 Receptor Measurements in Aging and in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to use brain imaging technology to study the effects of aging and Alzheimer's Disease (AD) on a specific type of brain receptor. The brain is made up of cells called neur…2005-04["Alzheimer's Disease","Healthy"]150——1999-04OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001917
NCT00001933NCT00001933Nefiracetam Therapy of Alzheimer's Type DementiaCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsSome of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells. Nefiracetam is a new d…2002-01["Alzheimer's Disease"]50—PHASE21999-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00001933
NCT00001972NCT00001972Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThe main source of energy for the brain comes from a combination of oxygen and glucose (sugar). For brain cells to function normally they must receive a constant supply of these nutrients. As areas of…2002-08["Alzheimer's Disease","Brain Neoplasm","Niemann Pick Disease"]123——1994-09OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001972
NCT00001977NCT00001977Cholinergic Modulation of Human Memory and Attention: Functional Neuroimaging StudiesCOMPLETEDnational-institute-of-mental-health-nimhThis study will examine whether enhancing the chemical acetylcholine in the brain can improve memory and attention. It will identify changes in brain function that occur during these cognitive tasks. …2001-04["Alzheimer's Disease","Healthy"]70——2000-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00001977
NCT00004845NCT00004845A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThe primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer…2001-12["Alzheimer Disease"]——PHASE2, PHASE3—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00004845
NCT00006176NCT00006176Clinical, Molecular and Biochemical Characterization of Familial Encephalopathy With Neuroserpin Inclusion BodiesCOMPLETEDnational-human-genome-research-institute-nhgriThe purpose of this study is to learn more about the medical problems and the genetic factors involved in a recently defined form of inherited dementia called "familial dementia with neuroserpin inclu…2009-08-04["Familial Dementia With Neuroserpin Inclusion Bodies","Nervous System Heredodegenerative Disorder"]100——2000-08-10OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00006176
NCT00006399NCT00006399Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's DiseaseCOMPLETEDnational-center-for-research-resources-ncrrThe goal of this study is to examine whether the administration of estrogen to post-menopausal women and women with mild to moderate Alzheimer's disease will enhance their memory and their capacity fo…2004-03["Alzheimer Disease"]45—PHASE21999-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00006399
NCT00007189NCT00007189Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)COMPLETEDseattle-institute-for-biomedical-and-clinical-researchThe purpose of this trial is to test the ability of the non-steroidal anti-inflammatory medications naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline.—["Alzheimer Disease"]2625—PHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00007189
NCT00009191NCT00009191The Depression in Alzheimer's Disease Study (DIADS)COMPLETEDjohns-hopkins-universityMajor depression afflicts approximately 25 percent of patients with AD. Depression in AD patients leads to mental suffering, behavioral disturbance (such as aggression), poor cognition, poor self-care…2007-11["Alzheimer Disease","Depression"]——PHASE42005-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009191
NCT00009204NCT00009204Serotonergic Pharmacotherapy for Agitation of DementiaCOMPLETEDbruce-pollockThis study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate …2002-04["Dementia","Alzheimer Disease","Dementia, Vascular"]——PHASE31995-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009204
NCT00009217NCT00009217Treatment of Behavioral Symptoms in Alzheimer's DiseaseCOMPLETEDnew-york-state-psychiatric-instituteThe optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse f…2004-12["Alzheimer's Disease","Psychosis","Agitation"]44ACTUALPHASE41999-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00009217
NCT00010803NCT00010803Ginkgo Biloba Prevention Trial in Older IndividualsCOMPLETEDnational-center-for-complementary-and-integrative-health-nccihThis study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, …2011-07["Dementia","Alzheimer's Disease"]3069ACTUALPHASE32000-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00010803
NCT00012831NCT00012831Nurse Managed Clinic for Dementia Patients and Family CaregiversCOMPLETEDus-department-of-veterans-affairsThis study evaluates the effectiveness of a nurse-managed interdisciplinary (nursing and occupational therapy) clinic serving community dwelling dementia patients and their spouse caregivers. It is gr…2001-06["Alzheimer's Disease","Caregivers","Dementia"]120ESTIMATED——OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00012831
NCT00012857NCT00012857Pain Management and Behavioral Outcomes in Patients With DementiaCOMPLETEDus-department-of-veterans-affairsDementia illness often co-exists with painful medical conditions associated with aging (e.g., degenerative joint disease, osteoarthritis, skin ulcers, back pain, headaches, cancer, or angina). While t…2001-03["Dementia","Alzheimer Disease, Pain","Behavior, Agitation"]66ESTIMATEDPHASE2—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00012857
NCT00013182NCT00013182Effect of Activity on Sleep of Cognitively-Impaired VeteransCOMPLETEDus-department-of-veterans-affairsSleep-activity rhythm disturbance is a prevalent, disabling symptom in cognitively-impaired (CI) elders. Their nocturnal sleep is light and inefficient with frequent awakenings. Multiple short daytime…2001-06["Alzheimer's Disease","Sleep Disorders"]90ESTIMATEDNA—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013182
NCT00013650NCT00013650Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to evaluate the effects of the drug cyclophosphamide (CY) on inflammation and immune responses in individuals with Alzheimer's Disease (AD). Inflammation and immunologic …2008-04-21["Alzheimer's Disease"]60—PHASE12001-03-22INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013650
NCT00013923NCT00013923A Nutritional Brain Metabolic Enhancer for Alzheimer DiseaseCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to evaluate the effectiveness of a nutritional supplement that has been developed to improve the brain function of a patient with Alzheimer's disease.2005-06["Alzheimer Disease"]40—PHASE2—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00013923
NCT00015548NCT00015548Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)COMPLETEDnational-institute-of-mental-health-nimhThe CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble …2004-10["Alzheimer's Disease"]450—NA2001-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00015548
NCT00017940NCT00017940A Phase I Study of Ex Vivo Nerve Growth Factor Gene Therapy for Alzheimer's DiseaseCOMPLETEDthe-shiley-family-trustThis Phase I clinical trial is the first step in testing gene therapy. This study is called a "Safety/Toxicity" study by the Food and Drug Administration, and primarily aims to determine whether the e…2003-11["Alzheimer Disease"]8—PHASE1—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00017940
NCT00018278NCT00018278Verbal Memory ERPs as Indices of Treatment Response in Alzheimer DiseaseCOMPLETEDus-department-of-veterans-affairsThe main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to…2001-09["Alzheimer Disease"]——PHASE41998-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018278
NCT00018291NCT00018291Specific Interventions for Agitation in Alzheimer's DiseaseCOMPLETEDus-department-of-veterans-affairsThis study is aimed at investigating specific pharmacological interventions in the treatment of the disruptive, agitated behavior associated with Alzheimer's patients. In addition, it is hoped that sp…2005-01["Alzheimer's Disease","Dementia"]——NA2001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018291
NCT00018343NCT00018343Alzheimer's Disease and Aging: Therapeutic Potential of EstrogenCOMPLETEDus-department-of-veterans-affairsThis study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.2001-03["Alzheimer's Disease"]——PHASE21998-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018343
NCT00018382NCT00018382Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic ApproachCOMPLETEDus-department-of-veterans-affairsThis study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.2003-03["Alzheimer Disease"]——PHASE21999-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00018382
NCT00018473NCT00018473Gene-Environment Interactions in Alzheimer's DiseaseCOMPLETEDus-department-of-veterans-affairsThis study will create Alzheimer 's disease risk profiles for defined combinations of genotypes and environmental exposures. This study will carry out a molecular epidemiologic study to identify genet…2004-03["Alzheimer's Disease"]———1999-04OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00018473
NCT00024531NCT00024531Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's DiseaseCOMPLETEDinstitute-for-the-study-of-aging-isoaThe purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.2004-08["Alzheimer Disease"]98—PHASE22000-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00024531
NCT00029120NCT00029120MRI Contrast Imaging in the Evaluation and Follow-up of Patients With Memory Disorder and Healthy ControlsCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to examine how a part of the brain called the hippocampus contributes to memory changes that occur with aging and Alzheimer's disease (AD). Memory problems are the most i…2008-04-21["Alzheimer Disease","Dementia","Memory Disorder","Healthy"]450——2001-12-18OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00029120
NCT00034567NCT00034567Alzheimer's Disease Prevention Instrument ProtocolCOMPLETEDnational-institute-on-aging-niaThis project will focus on the development and testing of efficient, cost effective measures that are specifically designed for use in Alzheimer's Disease (AD) primary prevention trials.—["Alzheimer Disease"]650———OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00034567
NCT00034762NCT00034762Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.COMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the efficacy and safety of risperidone compared with placebo in the treatment of psychotic symptoms in patients with Alzheimer's disease2003-01["Dementia","Alzheimer Disease","Mental Disorders"]473ACTUALPHASE32000-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00034762
NCT00035204NCT00035204A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Dis…COMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients wi…2003-05["Alzheimer Disease"]63ACTUALPHASE4—INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00035204
NCT00036114NCT00036114Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.2003-08["Alzheimer Disease"]——PHASE32000-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00036114
NCT00039702NCT00039702SPECT Imaging of Alpha4beta2 Nicotinic Acetylcholine Receptors Using [123I]5-I-A-85380 in Alzheimer's DiseaseCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to use brain imaging technology to examine the role of certain brain chemicals in individuals with Alzheimer's disease (AD) and in healthy volunteers. Cognitive dysfuncti…2004-09["Alzheimer Disease"]40——2002-06OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00039702
NCT00040378NCT00040378Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)COMPLETEDfrederick-schmittThe Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention tr…2016-08["Alzheimer Disease"]4246ACTUAL—2002-05OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00040378
NCT00040443NCT00040443Efficacy And Safety Of CX516 (900 mg t.i.d.) In Elderly Participants With Mild Cognitive Impairment. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group 4-week Study.COMPLETEDrespirerxGlutamate is fundamentally involved in learning and memory. Memory loss associated with mild cognitive impairment may be due to loss of glutamate receptors in the aging brain. There is evidence CX516 …2004-06["Mild Cognitive Impairment"]175ACTUALPHASE22002-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00040443
NCT00041678NCT00041678Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.2003-03["Alzheimer Disease"]——PHASE32000-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00041678
NCT00042172NCT00042172Cognitive Enhancers Explored With PET ImagingCOMPLETEDuniversity-of-iowaThe purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults. This study will also determine whether adding …2004-09["Cognition Disorders","Alzheimer Disease"]40—PHASE42002-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00042172
NCT00046358NCT00046358The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-AmyloidCOMPLETEDnational-institute-of-mental-health-nimhThe purpose of this study is to determine whether short-term use of the drugs ibuprofen and lovastatin affects levels of a protein called beta-amyloid in people who are at risk for developing Alzheime…2005-08["Alzheimer Disease"]50—PHASE42002-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00046358
NCT00051909NCT00051909Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's DiseaseCOMPLETEDeli-lilly-and-companyStudy of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.2003-06["Alzheimer's Disease"]200—PHASE22002-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00051909
NCT00053599NCT00053599A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaCLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly u…2007-10["Alzheimer Disease"]400—PHASE32002-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00053599
NCT00056225NCT00056225High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL)COMPLETEDnational-institute-on-aging-niaThe purpose of this study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons wi…2007-06["Alzheimer's Disease"]340ACTUALPHASE32003-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056225
NCT00056316NCT00056316Reducing Depression in Dementia CaregiversCOMPLETEDuniversity-of-missouri-st-louisThe purpose of this study was to develop and examine the initial impact of a distance-based intervention for female family dementia caregivers. As stated in the original proposal, the primary hypothes…2004-08["Depression"]74ACTUALPHASE1, PHASE22002-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056316
NCT00056524NCT00056524An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.COMPLETEDavanir-pharmaceuticalsThe purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolle…2007-06["Alzheimer's Disease","Stroke","Parkinson's Disease","Traumatic Brain Injury"]600ESTIMATEDPHASE32003-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056524
NCT00056628NCT00056628Study to Evaluate the Effect of Flow-Regulated Ventriculoperitoneal Shunting on Progression of Alzheimer's Disease: An Investigation of the Safety and Effectiveness of the COGNIShunt® CNS Shunt SystemCOMPLETEDeunoeThis is a study of the effect on the progression of Alzheimer's Disease of a surgically implanted shunt (tube) to increase the flow of cerebrospinal fluid and improve the clearance of potential neurot…2004-10["Alzheimer Disease"]250—PHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00056628
NCT00059410NCT00059410Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) IICOMPLETEDalzheimer-s-associationThe TIPS Study, or Treatment and Illness Perceptions Survey, is a study funded by the national Alzheimer's Association to learn more about differences between African Americans' and Whites' attitudes,…2005-09["Alzheimer Disease"]210——2003-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00059410
NCT00062569NCT00062569Reminiscence During Bathing Persons With Alzheimer's Disease at HomeCOMPLETEDnational-institute-of-nursing-research-ninrThis study will evaluate the effectiveness of a 3-week reminiscence intervention applied during bathing persons with Alzheimer's disease (AD) in decreasing resistiveness to care (RTC), relieving patie…2006-06["Alzheimer Disease"]90ACTUALNA2002-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00062569
NCT00063310NCT00063310Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN)COMPLETEDvoyager-pharmaceutical-corporationALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD). In women …2006-02["Alzheimer Disease"]90—PHASE22003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00063310
NCT00064870NCT00064870National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)RECRUITINGindiana-universityThe purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset …2026-07["Alzheimer Disease","Late Onset Alzheimer Disease","Dementia"]10000ESTIMATED—2002-06OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00064870
NCT00065169NCT00065169Anti-Inflammation in AD: PET Imaging SupplementCOMPLETEDuniversity-of-california-los-angelesThe purpose of this study is to determine whether the anti-inflammatory drug celecoxib can delay the onset of Alzheimer Disease (AD) in people with Age Associated Memory Impairment (AAMI). This study …2005-11["Alzheimer Disease","Dementia"]138—NA2000-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065169
NCT00065689NCT00065689High Intensity Light Therapy in Alzheimer's DiseaseCOMPLETEDnational-center-for-complementary-and-integrative-health-nccihThe purpose of this study is to determine whether bright light improves the sleep, mood, and behavior of persons with Alzheimer's disease and related dementias (AD) who live in long-term care settings…2005-09["Alzheimer's Disease","Dementia"]107—PHASE32003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065689
NCT00065767NCT00065767Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's DiseaseCOMPLETEDuniversity-of-wisconsin-madisonThe aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in imp…2005-03["Alzheimer Disease"]20—PHASE2, PHASE32001-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00065767
NCT00066157NCT00066157Alzheimer's Disease: Therapeutic Potential of EstrogenCOMPLETEDuniversity-of-wisconsin-madisonThis is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.2007-12["Alzheimer Disease"]42ACTUALPHASE2, PHASE32001-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00066157
NCT00071721NCT00071721A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)COMPLETEDalzheimer-s-disease-cooperative-study-adcsThe purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced …2009-12["Alzheimer Disease"]313ACTUALPHASE32003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00071721
NCT00073658NCT00073658Continuation Pharmacotherapy for Agitation of DementiaCOMPLETEDuniversity-of-pittsburghThis study will compare the safety and effectiveness two medications, citalopram (Celexa®) and risperidone (Risperdal®).2005-06["Dementia"]137—PHASE22000-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00073658
NCT00074529NCT00074529A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's DiseaseCOMPLETEDmerck-sharp-dohme-llcAn investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.2006-01["Alzheimer's Disease"]512ACTUALPHASE22003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00074529
NCT00076440NCT00076440Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 StudyCOMPLETEDvoyager-pharmaceutical-corporationALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 …2007-03["Alzheimer Disease"]90—PHASE22003-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00076440
NCT00082602NCT00082602Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's DiseaseCOMPLETEDjohnson-johnson-pharmaceutical-research-development-l-l-cThe purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.2005-04["Alzheimer's Disease"]83ACTUALPHASE32004-05INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00082602
NCT00083421NCT00083421Effects of ONO-2506PO in Patients With Alzheimer's DiseaseCOMPLETEDono-pharma-usa-incThe purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.2007-07["Alzheimer's Disease"]647ACTUALPHASE22004-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00083421
NCT00083590NCT00083590A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive FunctionCOMPLETEDnational-institute-on-aging-niaThe present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect on cognitive functio…2007-11["Alzheimer Disease"]150ESTIMATEDPHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00083590
NCT00086138NCT00086138Depression in Alzheimer's Disease (DIADS-2)COMPLETEDjohns-hopkins-universityThe purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's…2009-07["Alzheimer's Disease","Depression"]131ACTUALPHASE2, PHASE32004-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00086138
NCT00087789NCT00087789A Phase I, Dose-Escalating Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-Based Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects With Mild…COMPLETEDsangamo-therapeuticsThis is a Phase I clinical study to assess the safety, tolerability and biologic activity of in vivo AAV-mediated delivery of CERE-110. Up to 12 subjects will receive open label CERE-110 in dose-escal…2010-05["Alzheimer's Disease"]10ACTUALPHASE12004-06INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00087789
NCT00088387NCT00088387Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's DiseaseCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsThis study will examine the effect of the drugs lithium and divalproex (Depakote) on tau proteins, a type of protein in the brain and spinal fluid that are altered in patients with Alzheimer's disease…2005-03["Alzheimer Disease"]35—PHASE22004-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00088387
NCT00088751NCT00088751Treatment Study for Frontotemporal DementiaCOMPLETEDnational-institute-of-neurological-disorders-and-stroke-nindsObjectives. The proposed clinical study has two goals: First, to assess the efficacy of a central nervous system stimulant and an atypical antipsychotic in treating the behavioral symptoms of FTD and …2009-06-01["Frontotemporal Lobar Degeneration"]20——2004-07-23OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00088751
NCT00089882NCT00089882Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IICOMPLETEDnational-institute-on-aging-niaThe REVEAL II study provides healthy adult children and siblings of Alzheimer's disease patients with genetic testing and information about their own chances of developing the disease. The study will …2006-09["Alzheimer Disease"]360——2003-05OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00089882
NCT00090116NCT00090116A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's TypeCOMPLETEDforest-laboratoriesMemory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells…2005-03["Alzheimer's Disease"]400—PHASE32003-03INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00090116
NCT00090402NCT00090402Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's DiseaseCOMPLETEDoregon-health-and-science-universityThe purpose of this study is to determine the effect of fish oil and the antioxidant alpha lipoic acid on factors in the blood that are associated with the progression of Alzheimer's Disease (AD).2007-08["Alzheimer's Disease","Oxidative Stress","Dementia","Hyperlipidemia","Inflammation"]39ACTUALPHASE1, PHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00090402
NCT00093951NCT00093951A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's DiseaseCOMPLETEDsaegis-pharmaceuticalsThe purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.2007-09["Alzheimer's Disease"]280—PHASE22004-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00093951
NCT00095719NCT00095719A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaCOMPLETEDotsuka-pharmaceutical-development-commercialization-incThe purpose of this trial is to test the safety \& tolerability of intramuscular aripiprazole in acutely agitated patients diagnosed with Dementia.2005-03["Dementia","Alzheimer's Disease"]125—PHASE32003-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00095719
NCT00096473NCT00096473A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a …COMPLETEDeisai-incDonepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, ac…2005-09["Alzheimer's Disease","Dementia"]229ACTUALPHASE32001-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00096473
NCT00097916NCT00097916A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's DiseaseCOMPLETEDforest-laboratoriesAbout 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associat…2006-04["Alzheimer's Disease"]34ACTUALPHASE32004-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00097916
NCT00099242NCT00099242Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCOMPLETEDnovartis-pharmaceuticalsThe goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.2006-01["Alzheimer's Disease","Dementia, Alzheimer Type"]1040—PHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00099242
NCT00099567NCT00099567Metabolic Syndrome, Inflammation, and Risk of Cognitive DeclineCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to determine if the metabolic syndrome is a risk factor for cognitive decline and if this association is modified by inflammation.2002-12["Cognitive Decline"]2632——1997-01OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00099567
NCT00099710NCT00099710A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's DiseaseCOMPLETEDjohn-douglas-french-foundationThe purpose of this study is to examine the safety and tolerability of curcumin, and to determine its effect on patients with mild to moderate Alzheimer's Disease (AD).2007-12["Alzheimer's Disease"]33ESTIMATEDPHASE22003-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00099710
NCT00100282NCT00100282Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's DiseaseCOMPLETEDpraecis-pharmaceuticals-incThis is a multi-center, double-blind, inpatient study followed by outpatient, placebo-controlled, single-dose, dose-escalation evaluation of the safety and tolerability of PPI-1019 in patients with mi…2005-06["Alzheimer's Disease"]125—PHASE12003-05INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00100282
NCT00100334NCT00100334Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's DiseaseCOMPLETEDpraecis-pharmaceuticals-incThis is a single-center, double-blind, inpatient study followed by an outpatient, placebo-controlled, multiple-IV injection evaluation of the safety and tolerability of PPI-1019 in subjects with mild-…2005-08["Alzheimer's Disease"]24—PHASE1, PHASE22004-12INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00100334
NCT00103649NCT00103649A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCOMPLETEDsanofiThe purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patient…2007-10["Alzheimer Disease"]1306ACTUALPHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00103649
NCT00104013NCT00104013A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCOMPLETEDsanofiThe purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patient…2007-11["Alzheimer Disease"]1455ACTUALPHASE32003-11INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104013
NCT00104273NCT00104273A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's TypeCOMPLETEDteva-branded-pharmaceutical-products-r-d-incThe purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are t…—["Dementia","Alzheimer's Disease"]376ACTUALPHASE22004-08INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104273
NCT00104442NCT00104442Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseCOMPLETEDnovartisAlzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, pla…2006-04["Alzheimer's Disease"]80—PHASE42003-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00104442
NCT00105547NCT00105547Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subj…COMPLETEDmyrexis-incThe purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of…2008-05["Alzheimer Disease","Dementia"]1600ACTUALPHASE32005-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105547
NCT00105612NCT00105612Improving Informed Consent in Alzheimer's Disease ResearchCOMPLETEDnational-institute-on-aging-niaThe purpose of this trial is to test whether a memory and organizational aid in the form of a document that summarizes and simplifies a study's key points can improve the decision-making abilities and…2007-03["Alzheimer's Disease","Aging"]110—NA2004-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105612
NCT00105638NCT00105638A Telehealth Education Program for Caregivers of Veterans With DementiaCOMPLETEDus-department-of-veterans-affairsThis study was designed to evaluate the impact of a Telehealth Education Program (TEP) on outpatient veterans with moderate to severe dementia and their spouse caregivers. The TEP is a program of educ…2007-04["Dementia","Alzheimer Disease"]160ESTIMATEDNA2005-09INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00105638
NCT00106899NCT00106899Alzheimer's Disease Neuroimaging InitiativeCOMPLETEDalzheimer-s-disease-cooperative-study-adcsThe purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This…2011-06["Alzheimer's Disease"]818ACTUAL—2005-07OBSERVATIONALhttps://clinicaltrials.gov/study/NCT00106899
NCT00110552NCT00110552Effects of a Cognitive Enhancer on Memory and Cognitive PerformanceCOMPLETEDoregon-health-and-science-universityThe purpose of this study is to determine the effectiveness of the herb sage in improving the mental function of individuals with Alzheimer's disease. Study hypothesis: The administration of sage wil…2014-10["Alzheimer Disease"]111ACTUALPHASE12005-07INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00110552
NCT00112073NCT00112073A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients…COMPLETEDjanssen-alzheimer-immunotherapy-research-development-llcThe purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).2008-12["Alzheimer's Disease"]234ACTUALPHASE22005-04INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00112073
NCT00117403NCT00117403Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's DiseaseCOMPLETEDnational-institute-on-aging-niaThe purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include v…2007-09["Alzheimer's Disease"]75ESTIMATEDPHASE12006-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00117403
NCT00119561NCT00119561Testing the Effectiveness of Telephone Support for Dementia CaregiversCOMPLETEDus-department-of-veterans-affairsThe primary goal of the study is documentation of effectiveness of telephone support groups to reduce caregiver burden and stress. Caregivers who participate in intervention (Telephone Support) should…2014-01["Dementia","Alzheimer Disease"]154ACTUALNA2005-02INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00119561
NCT00120874NCT00120874Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled TrialCOMPLETEDnyu-langone-healthThe purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwellin…2011-11["Alzheimer's Disease"]20ACTUALPHASE42006-08INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00120874
NCT00130429NCT00130429Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the…COMPLETEDphytopharmThe purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.2005-09["Alzheimer's Disease"]250—PHASE22004-01INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00130429
NCT00141661NCT00141661A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability o…COMPLETEDpfizerA 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.2006-06["Alzheimer Disease"]67ACTUALPHASE22005-10INTERVENTIONALhttps://clinicaltrials.gov/study/NCT00141661